Immunoregulatory functions of <scp>VISTA</scp>
Elizabeth C. Nowak(Dartmouth College), J. Louise Lines(Dartmouth College), Frederick S. Varn(Dartmouth College), Jie Deng(Dartmouth College), Aurélien Sarde(Dartmouth College), Rodwell Mabaera(Dartmouth College), Anna Kuta(Dartmouth College), Isabelle Le Mercier(ImmuNext (United States)), Chao Cheng(Dartmouth College), Randolph J. Noelle(Dartmouth College)
Cited by 191
Abstract
Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Ig-containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.